Natural Killer T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Natural Killer T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy [Phase 2]
Phase 2 trial evaluating the combination of isatuximab and cemiplimab in relapsed or refractory Natural Killer/T-cell lymphoma has completed…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL [Phase 2]
Phase 2 trial evaluating PD-1 antibody-based therapy with concurrent radiation therapy for early-stage natural killer/T-cell lymphoma; curre…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) [Phase 1]
Electra Therapeutics is conducting a Phase 1 trial of ELA026 in relapsed/refractory T-cell and NK/T-cell malignancies, and the study is curr…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
A Sun Yat-sen University-led clinical trial is evaluating a multi-modal fusion model and deep learning approach to predict treatment respons…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ATG-010 in combination with chemotherapy with maintenance ATG-010 in Peripheral T-cell lymphoma and natural kil…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma [Phase 2]
This clinical trial assesses maintenance therapy with selinexor plus azacitidine after allogeneic stem cell transplantation in patients with…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL [Phase 1, Phase 2]
Phase Ib/II clinical study evaluating tislelizumab combined with golidocitinib and selinexor for relapsed/refractory natural killer/T-cell l…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies [Phase 1]
A Phase 1 clinical trial (NCT06699771) is evaluating the safety, tolerability, and preliminary efficacy of GCC2005. The trial focuses on pat…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
This clinical trial update describes a study evaluating PET imaging targeting Granzyme B as a biomarker to predict efficacy and prognosis in…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
This clinical study assesses whether artificial intelligence-enhanced 18F-FDG PET/CT can aid differential diagnosis, predict treatment effic…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies [Phase 1]
Phase 1 clinical trial update for RD13-02 cell injection in patients with relapsed or refractory CD7-positive natural killer/T-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma [Phase 2]
Phase 2 clinical trial update for a regimen of PEG-ASP, etoposide, and gemcitabine for natural killer/T-cell lymphoma is reported, with the …
-
CLINICAL_TRIALS trial_result · 2022-06-09Clinical Trial Update: Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a combination of sintilimab, peg-aspargase, and anlotinib for Natural Killer/T-Cell Lymphoma (nasal/nasal-type) h…
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anlotinib in advanced and refractory natural killer / T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update investigating dexamethasone, azacytidine, pegaspargase, and tislelizumab for NK/T cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type [Phase 2]
Phase 2 clinical trial assessing daratumumab for relapsed or refractory natural killer/T-cell lymphoma, nasal type; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage [Phase 2]
Phase 2 trial comparing PEG-ASP+Gemoxd versus PEG-ASP+CHOP as first-line chemotherapy for early-stage NK/T-cell lymphoma; status and results…
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma [Phase 4]
A Phase 4 clinical trial evaluating a combination of a PD-1 antibody, chidamide, lenalidomide, and etoposide for relapsed or refractory NK/T…
-
CLINICAL_TRIALS trial_result · 2017-01-20Clinical Trial Update: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas [Phase 1]
Phase 1 study evaluating CHOP chemotherapy plus Campath-1H (alemtuzumab) as initial treatment for untreated aggressive T/NK-cell non-Hodgkin…
-
CLINICAL_TRIALS trial_result · 2010-09-08Clinical Trial Update: Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating a dexamethasone–ifosfamide–cisplatin–etoposide regimen in natural ki…
-
CLINICAL_TRIALS trial_result · 2009-10-14Clinical Trial Update: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas [Phase 1, Phase 2]
A completed Phase 1/2 clinical study evaluated combining bortezomib with CHOP chemotherapy in patients with advanced aggressive T-cell lymph…